As fixed-income CEFs appreciate, investors seeking yield should be cognizant of bond rollover into lower-yielding assets as well as the added risk of leverage, says RiverNorth's Patrick Galley.
Blockbuster sales and takeover potential create an attractive risk/reward tradeoff for this speculative biotech.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.
Miss any of Morningstar's Ideas Week? See the whole lineup, including our most popular articles and videos.
©2012 Morningstar Advisor. All right reserved.